Clinical effect of Yangxinshi Tablets combined with Sacubitril Valsartan Sodium in the treatment of chronic heart failure in elderly patients
TANG Ai1 YANG Gui-zhi2▲
1.Department of Ultrasonography,Ji′nan Hospital of Integrated Traditional Chinese and Western Medicine,Shandong Province,Ji′nan 271100,China;
2.Department of Geriatrics,Ji′nan Hospital of Integrated Traditional Chinese and Western Medicine,Shandong Province,Ji′nan 271100,China
Abstract：Objective To investigate the clinical effect of Yangxinshi Tablets combined with Sacubitril Valsartan Sodium(ARNI)in the treatment of elderly patients with chronic heart failure.Methods A total of 120 elderly patients with CHF admitted to Ji′nan Hospital of Integrated Traditional Chinese and Western Medicine from June 2018 to December 2019 were selected as the research objects and divided into treatment group(60 cases)and control group(60 cases)according to random number table method.The control group was treated with standard treatment,and the treatment group was treated with Yangxinshi Tablets combined with ARNI on the basis of the control group.The total effective rate,left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD)and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment group was higher than that of control group,the difference was statistically significant(P＜0.05).After treatment,LVEF of the two groups were higher than before treatment,while LVEDD were lower than before treatment,and LVEF of the treatment group was higher than that of the control group,LVEDD of the treatment group was lower than that of the control group,the differences were statistically significant(P＜0.05).There were no obvious adverse reactions such as hypotension during treatment in two groups.Conclusion Yangxinshi Tablets combined with ARNI can significantly improve the clinical symptoms of elderly patients with CHF,improve cardiac ultrasound index,reverse ventricular remodeling,and have good safety.
Vecchis R，Cesaro A，Ariano C.Therapeutic benefits of phosphodi-esterase-5 inhibition in chronic heart failure：a meta-analysis[J].Interv Med Appl Sci，2017，9（3）：123-135.
[2]
Zhang Y，Zhang J，Butler J，et al.Contemporary epidemiology，management，and outcomes of patients hospitalized for heart failure in China：results from the China Heart Failure（China-HF）Registry[J].J Card Fail，2017，23（12）：868-875.
[3]
Petrov VN，Agaeva EV，Popovkina OE，et al.Modifying effect of autotransfusion of mesenchymal stromal cells on the production of reactive oxygen species and cytokines by mononuclear cells in patients with chronic heart failure[J].Bull Exp Biol Med，2017，164（2）：233-240.
[5]
Zile MR，Brutsaert DL.New concepts in diastolic dysfunction and diastolic heart failure：part I:diagnosis.prognosis.measurement of diastolic function[J].Circulation，2002，105（10）：1387-1393.
[6]
Cody RJ，Haas GJ，Binkley PF，et al.Plasma endothelin correlate with the extent of pulmonary hypertension in patients with chronic congestive heart failure[J].Circulation，1992，85（2）：504-509.
[7]
CONSENSUS Trial Study Group.Effects of enalapril on mortality in severe congestive heart failure.Results of the Cooperative North Scandinavian Enalapril Survival Study（CONSENSUS）[J].N Engl J Med，1987，316(23):1429-1435.
[8]
Mc Murray JJ，Packer M，Desai AS，et al.Angiotensi-neprilysin inhibition versus enalapril in heart failure[J].N Engl J Med，2014，371（11）：993-1004.
京公网安备 11010502046607号